Regencell Bioscience Holdings Stock Today
| RGC Stock | USD 41.00 17.63 30.07% |
PerformanceGood
| Odds Of DistressBelow Average
|
Regencell Bioscience is trading at 41.00 as of the 24th of March 2025, a 30.07 percent decrease since the beginning of the trading day. The stock's open price was 58.63. Regencell Bioscience has about a 38 percent probability of financial distress in the next few years of operation but had a somewhat good performance during the last 90 days. Note, on December 21, 2017, Senator Michael Bennet of US Senate acquired $500,001 - $1,000,000 worth of Regencell Bioscience's common stock.
Business Domain Pharmaceuticals, Biotechnology & Life Sciences | IPO Date 16th of July 2021 | Category Healthcare | Classification Health Care |
Regencell Bioscience Holdings Limited operates a Traditional Chinese medicine bioscience company. The company was incorporated in 2014 and is headquartered in Causeway Bay, Hong Kong. Regencell Bioscience operates under Drug ManufacturersSpecialty Generic classification in the United States and is traded on NASDAQ Exchange. The company has 13.01 M outstanding shares of which 18.18 K shares are at this time shorted by investors with about 0.32 days to cover. More on Regencell Bioscience Holdings
Moving against Regencell Stock
Regencell Stock Highlights
ESG Sustainability
Environmental | Governance | Social |
| Thematic Idea | Compulsion (View all Themes) | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Old Names | [Heliostar Metals Ltd, PV - Inconess Investment Corp, Regal Entertainment Group] | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Business Concentration | Biotechnology, Pharmaceuticals, Biotechnology & Life Sciences, Health Care, NASDAQ Composite, NASDAQ Health Care, Compulsion, Health Care, Biotechnology, Drug Manufacturers—Specialty & Generic, Healthcare (View all Sectors) | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Financial Strength
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Debt LevelsRegencell Bioscience can leverage the use of borrowed funds to amplify returns from an investment. In general, analyzing the relationship between debt to total assets helps investors to understand Regencell Bioscience's financial leverage. It provides some insight into what part of Regencell Bioscience's total assets is financed by creditors.
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Regencell Bioscience Holdings (RGC) is traded on NASDAQ Exchange in USA. It is located in Chinachem Leighton Plaza, Causeway Bay, Hong Kong and employs 12 people. Regencell Bioscience is listed under Biotechnology category by Fama And French industry classification. The company currently falls under 'Small-Cap' category with a total capitalization of 533.53 M. Regencell Bioscience runs under Biotechnology sector within Health Care industry. The entity has 13.01 M outstanding shares of which 18.18 K shares are at this time shorted by investors with about 0.32 days to cover.
Regencell Bioscience Holdings has about 59.41 K in cash with (4 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 0.01.
Check Regencell Bioscience Probability Of Bankruptcy
Ownership AllocationThe market capitalization of Regencell Bioscience is $533.53 Million. Regencell Bioscience holds majority of its outstanding shares owned by insiders. An insider is usually defined as a corporate executive, director, member of the board or institutional investor who own at least 10% of the company's outstanding shares. 93.83 pct. of Regencell Bioscience outstanding shares that are owned by insiders implies they have been buying or selling the stock in recent months in anticipation of some upcoming event. Please note that on December 21, 2017, Senator Michael Bennet of US Senate acquired $500,001 - $1,000,000 worth of Regencell Bioscience's common stock.
Check Regencell Ownership Details
Regencell Stock Institutional Holders
| Instituion | Recorded On | Shares | |
| Ubs Group Ag | 2024-12-31 | 29.2 K | |
| Morgan Stanley - Brokerage Accounts | 2024-12-31 | 2.1 K | |
| Blackrock Inc | 2024-12-31 | 238 | |
| Qube Research & Technologies | 2024-09-30 | 0.0 |
Regencell Bioscience Historical Income Statement
Regencell Stock Against Markets
Regencell Bioscience Corporate Management
| Wai Chung | COO Officer | Profile | |
| Tien Chau | Executive Officer | Profile | |
| Michelle Chan | Financial Controller | Profile | |
| YatPui Au | Chief Officer | Profile | |
| YatGai Au | Chairman Founder | Profile | |
| Antonia Assang | Senior Management | Profile |
Check out Your Equity Center to better understand how to build diversified portfolios, which includes a position in Regencell Bioscience Holdings. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in price. You can also try the Bond Analysis module to evaluate and analyze corporate bonds as a potential investment for your portfolios..
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Regencell Bioscience. If investors know Regencell will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Regencell Bioscience listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
The market value of Regencell Bioscience is measured differently than its book value, which is the value of Regencell that is recorded on the company's balance sheet. Investors also form their own opinion of Regencell Bioscience's value that differs from its market value or its book value, called intrinsic value, which is Regencell Bioscience's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Regencell Bioscience's market value can be influenced by many factors that don't directly affect Regencell Bioscience's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Regencell Bioscience's value and its price as these two are different measures arrived at by different means. Investors typically determine if Regencell Bioscience is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Regencell Bioscience's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.